The effects of alpha-lipoic acid supplementation on inflammatory markers among patients with metabolic syndrome and related disorders: a systematic review and meta-analysis of randomized controlled trials

Table 2 Estimation of the standardized difference means of related indictors with CI 95% between the intervention and placebo groups

Variables		Number of study	Standardized mean difference	CI 95%	Heterogeneity
Variables		Number of study	Standardized mean difference	CI 95%	I² (%)	Q	P-value
CRP	Intervention group (after vs. before)	11	−0.88	−1.55, − 0.21	92.4	130.85	< 0.001
	Placebo group (after vs. before)	11	−0.29	− 0.67, 0.09	80.3	50.87	< 0.001
	Change intervention group vs. placebo group	13	−1.52	−2.25, −0.80	93.7	191.17	< 0.001
IL-6	Intervention group (after vs. before)	13	−0.99	−1.48, − 0.51	85.0	79.92	< 0.001
	Placebo group (after vs. before)	13	0.03	−0.16, 0.22	17.8	14.59	0.264
	Change intervention group vs. placebo group	15	−1.96	−2.60, − 1.32	90.6	149.58	< 0.001
TNF-α	Intervention group (after vs. before)	10	−1.41	−2.03, −0.79	87.0	69.13	< 0.001
	Placebo group (after vs. before)	10	−0.33	− 0.72, 0.05	71.4	31.50	< 0.001
	Change intervention group vs. placebo group	10	−2.62	−3.70, −1.55	94.3	157.51	< 0.001

IL-6 interlokin-6, CRP C-reactive protein, TNF-α tumor necrosis factor alpha

ISSN: 1743-7075